Shareholders Join Suits In XenoPort Stock Price Case

Law360, New York (January 5, 2011, 5:33 PM EST) -- XenoPort Inc. shareholders have lodged a consolidated class action based on two earlier suits claiming the company withheld information that caused federal regulators to block approval of a restless leg syndrome drug it developed with GlaxoSmithKline PLC, allegedly inflating share prices.

Lead plaintiff Ie-Chen Cheng alleges that biopharmaceutical company XenoPort failed to disclose studies showing a link between the developmental drug Horizant and an increased risk of pancreatic cancer in laboratory rats, according to a consolidated complaint filed Tuesday in the U.S. District Court for the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.